Aaron Wealth Advisors LLC Has $1.24 Million Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Aaron Wealth Advisors LLC grew its stake in AstraZeneca PLC (NASDAQ:AZN) by 8.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 18,842 shares of the company’s stock after purchasing an additional 1,440 shares during the quarter. Aaron Wealth Advisors LLC’s holdings in AstraZeneca were worth $1,235,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AZN. Veery Capital LLC lifted its stake in AstraZeneca by 4.7% in the 4th quarter. Veery Capital LLC now owns 3,503 shares of the company’s stock valued at $230,000 after acquiring an additional 157 shares in the last quarter. Ameritas Advisory Services LLC grew its position in shares of AstraZeneca by 25.9% during the 4th quarter. Ameritas Advisory Services LLC now owns 9,487 shares of the company’s stock worth $622,000 after purchasing an additional 1,949 shares in the last quarter. Trust Co. of Vermont increased its stake in AstraZeneca by 91.1% during the 4th quarter. Trust Co. of Vermont now owns 1,204 shares of the company’s stock worth $79,000 after acquiring an additional 574 shares during the period. Sanibel Captiva Trust Company Inc. raised its position in AstraZeneca by 8.1% during the fourth quarter. Sanibel Captiva Trust Company Inc. now owns 19,605 shares of the company’s stock valued at $1,285,000 after purchasing an additional 1,477 shares in the last quarter. Finally, Howard Financial Services LTD. boosted its stake in shares of AstraZeneca by 14.4% in the 4th quarter. Howard Financial Services LTD. now owns 4,850 shares of the company’s stock valued at $318,000 after purchasing an additional 610 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

AZN stock opened at $66.60 on Friday. The firm’s fifty day moving average is $66.11 and its 200 day moving average is $74.49. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. The firm has a market cap of $206.50 billion, a P/E ratio of 31.87, a P/E/G ratio of 1.05 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter last year, the firm earned $0.87 earnings per share. The business’s revenue for the quarter was up 18.0% on a year-over-year basis. Research analysts predict that AstraZeneca PLC will post 4.11 earnings per share for the current year.

Analyst Ratings Changes

AZN has been the topic of a number of recent analyst reports. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.